Drug Information

Drug General Information
Drug ID
D01AYX
Former ID
DNCL003369
Drug Name
AZD3293
Drug Type
Small molecular drug
Indication Alzheimer disease [ICD9: 331; ICD10:G30] Phase 2/3 [524922], [542739]
Company
AstraZeneca
Structure
Download
2D MOL
Formula
C26H28N4O
InChI
InChI=1S/C26H28N4O/c1-4-5-18-12-21(16-28-15-18)19-6-7-20-14-25(10-8-22(31-3)9-11-25)26(23(20)13-19)29-17(2)24(27)30-26/h6-7,12-13,15-16,22H,8-11,14H2,1-3H3,(H2,27,30)
InChIKey
WKDNQONLGXOZRG-UHFFFAOYSA-N
PubChem Compound ID
57404290
PubChem Substance ID
136949781, 163330484, 163342123, 223366120, 235297992, 235298211
Target and Pathway
Target(s) Beta-secretase Target Info Modulator [551416]
References
Ref 524922ClinicalTrials.gov (NCT02245737) An Efficacy and Safety Study of AZD3293 in Early Alzheimer's Disease. U.S. National Institutes of Health.
Ref 542739(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7789).
Ref 551416AZD3293 A novel BACE1 inhibitor: safety, tolerability, and effects on plasma and CSF A-beta peptides following single- and multiple-dose administration. Neurobiology of Aging. May 20, 2008.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.